References
- Schlander M, Garattini S, Holm S, Kolominsky-Rabas P, Nord E, Persson U, etal. Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Eff Res. 2014; 3(4): 399–422.
- NICE Citizens Council. NICE Citizens Council report: ultra orphan drugs. 2004; London. Available from: www.nice.org.uk/niceMedia/pdf/Citizens_Council_Ultraorphan.pdf [cited 5 May 2016]..
- Schlander M, Beck M. Expensive drugs for rare disorders: To treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI. Curr Med Res Opin. 2009; 25(5): 1285–93.
- Alcimed. Study on orphan drugs. 2005; Part I. Paris: Alcimed. Available from: http://ec.europa.eu/enterprise/pharmaceuticals/orphanmp/doc/pricestudy/final_final_report_part_1_web.pdf [cited 5 May 2016]..
- Hughes-Wilson W, Palma A, Schuurman A, Simoens S. Paying for the orphan drug system: Break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?. Orphanet J Rare Dis. 2012; 7(74): 1–8.
- Joppi R, Bertele’ V, Garattini S. Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU. Eur J Clin Pharmacol. 2013; 69(4): 1009–24.
- Tobin J. On limiting the domain of inequality. J Law Econ. 1970; 13: 263–77.
- Torrance GW. Utility measurement in healthcare: The things I never got to. Pharmacoeconomics. 2006; 24(11): 1069–78.
- Schey C, Milanova T, Hutchings A. Estimating the budget impact of orphan medicines in Europe: 2010–2020. Orphanet J Rare Dis. 2011; 6(2): 1–10.
- Gafni A, Birch S. Incremental cost–effectiveness ratios (ICERs): The silence of the lambda. Soc Sci Med. 2006; 62: 2091–100.
- Richardson J, McKie J. Economic evaluation of services for a National Health Scheme: The case for a fairness-based framework. J Health Econ. 2007; 26(4): 785–99.
- Nord E. Cost-value analysis in health care. Making sense out of QALYs. 1999; Cambridge, UK: Cambridge University Press.